Trial reportBrain and behavior2025
Effect of Probucol and Atorvastatin Treatment on the Self-Care Ability of Acute Cerebral Infarction Patients: A Randomized Clinical Trial Study.
Trial report in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundTo investigate the effect of probucol and atorvastatin on self-care ability in patients with acute cerebral infarction (ACI).
methodsEighty-one patients with ACI admitted from November 2020 to May 2021 were divided into a combination treatment group (n = 40) and an atorvastatin group (n = 41). The atorvastatin group was given atorvastatin on the basis of conventional treatment, and the combination treatment group was treated with probucol and atorvastatin on the control basis. Self-care ability and blood lipid levels were assessed at baseline and 6 months after treatment using the Barthel Index (BI) and biochemical tests. The study also included MRI scans to evaluate infarct volume and monitored relevant clinical indicators.
resultsThe baseline data of both groups were consistent and comparable. After six months, both groups showed improved self-care ability, with the combined treatment group exhibiting a more significant improvement (P < 0.05). The combination treatment group also demonstrated a significant reduction in total cholesterol (TCH) and low-density lipoprotein (LDL) levels compared to the atorvastatin group (P < 0.05). The factors influencing self-care ability included history of cerebrovascular disease, treatment modality, and LDL levels.
conclusionProbucol combined with atorvastatin significantly enhances self-care ability and improves blood lipid levels in patients with ACI. This combination therapy is safe, feasible, and recommended for clinical application to reduce cognitive decline and improve quality of life in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.